Suzhou Zion Pharma Technology Co Ltd. has identified KRAS inhibitors, in particular GTPase KRAS G12D mutant and/or G13D mutant, reported to be useful for the treatment of cancer.
Suzhou Zion Pharma Technology Co. Ltd. has described transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) and/or probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer and viral infections.
Suzhou Zion Pharma Technology Co. Ltd. has identified GTPase KRAS G12D or G13D mutant and/or KRAS inhibitors reported to be useful for the treatment of cancer.
Suzhou Zion Pharma Technology Co. Ltd. has reported GTPase KRAS (G12C mutant) inhibitors described as potentially useful for the treatment of brain cancer.
Suzhou Zion Pharma Technology Co. Ltd. has divulged serine-protein kinase ATM (ataxia telangiectasia mutated) inhibitors reported to be useful for the treatment of cancer.
